CN113786460B

CN113786460B - Plant composition capable of relieving diarrhea-predominant irritable bowel syndrome

Info

Publication number: CN113786460B
Application number: CN202111077446.0A
Authority: CN
Inventors: 李家炜; 闫昌誉; 叶健文; 王志芳; 罗莉莉; 何蓉蓉; 栗原博; 古润金
Original assignee: Guangdong Perfect Life Health Technology Research Institute Co ltd; Perfect China Co Ltd; Perfect Guangdong Commodity Co Ltd
Current assignee: Guangdong Perfect Life Health Technology Research Institute Co ltd; Perfect China Co Ltd; Perfect Guangdong Commodity Co Ltd
Priority date: 2021-09-14
Filing date: 2021-09-14
Publication date: 2022-05-17
Anticipated expiration: 2041-09-14
Also published as: CN113786460A

Abstract

The invention discloses a plant composition capable of relieving diarrhea-predominant irritable bowel syndrome, and belongs to the field of plant composition application. The plant composition disclosed by the invention takes gynura procumbens as a main component, and simultaneously takes the perilla frutescens, the lophatherum gracile, the platycodon grandiflorum and the poria cocos to generate a synergistic effect together, so that the symptoms of diarrhea-type irritable bowel syndrome can be remarkably improved and relieved, and the composition is safe and has no toxic or side effect. The invention also discloses a preparation method of the plant composition and a medicinal preparation prepared from the plant composition and capable of relieving diarrhea-predominant irritable bowel syndrome.

Description

Plant composition capable of relieving diarrhea-predominant irritable bowel syndrome

Technical Field

The invention relates to the field of application of plant compositions, in particular to a plant composition capable of relieving diarrhea-predominant irritable bowel syndrome.

Background

Irritable Bowel Syndrome (IBS), also known as Irritable bowel syndrome or Irritable bowel syndrome, is a gastrointestinal dysfunction disease with persistent or intermittent episodes of abdominal pain, abdominal discomfort, constipation or diarrhea, and altered bowel habits. IBS, however, lacks specific clinical morphological and pathological changes in the gastrointestinal tract and biochemical abnormalities. IBS is divided into the following subtypes according to stool characteristics: (1) constipation-type IBS (IBS-Constipation): the proportion of hard excrement or block excrement is more than or equal to 25 percent, and the proportion of loose excrement or water sample excrement is less than 25 percent; (2) diarrhea type DIBS (IBS-Diarrhea): the proportion of loose excrement or water sample excrement is more than or equal to 25 percent, and the proportion of hard excrement or block excrement is less than 25 percent; (3) mixed IBS (IBS-Mixed): the proportion of hard excrement or block excrement is more than 25 percent, and the proportion of loose excrement or water sample excrement is more than or equal to 25 percent; (4) indeterminate IBS (IBS-Unscubtyped): the stool character is not consistent with the three subtypes. The pathophysiological mechanism of IBS is not yet clarified, the research on the pathogenesis of IBS mostly focuses on visceral hypersensitivity and relates to multiple levels of nervous system, and a large number of researches prove that the central nervous system is involved in regulating gastrointestinal tract activity, absorption, secretion and the like. In addition, IBS patients are often associated with emotional anxiety and depression, the onset of which is also closely related to environmental factors and mental stress.

Until now, no therapeutic drug for IBS exists clinically, and symptomatic methods such as antidiarrheal, spasmolysis and pain relieving, intestinal flora regulating and the like are generally adopted, and although the methods have a certain relieving effect, the methods are easy to relapse after the drug is stopped. Therefore, attention is paid to the development and development of a therapeutic method for IBS while analyzing the pathophysiology thereof. From the perspective of physical health and living habits, there is a need for a medical product for improving or treating IBS diseases, which can be taken for a long time and has high safety, and has a good effect of preventing and improving IBS.

Disclosure of Invention

Based on the defects of the prior art, the invention aims to provide the plant composition capable of relieving diarrhea-predominant irritable bowel syndrome, the composition takes gynura procumbens as a main component, and simultaneously takes the synergistic effect of perilla, lophatherum gracile, platycodon grandiflorum and poria cocos together, the symptoms of diarrhea-predominant irritable bowel syndrome DIBS can be remarkably improved and relieved, and the composition is safe and has no toxic or side effect.

In order to achieve the purpose, the invention adopts the technical scheme that:

a plant composition capable of relieving diarrhea-predominant irritable bowel syndrome comprises the following raw materials in parts by weight:

40-50 parts of gynura procumbens, 10-18 parts of purple perilla, 15-25 parts of lophatherum gracile, 20-26 parts of platycodon grandiflorum and 12-22 parts of poria cocos.

Most of the existing medicines for relieving the DIBS symptoms have the defects of short effect, weak effect, temporary solution treatment, no permanent cure, great side effect and the like, and the inventor of the application finds that the products prepared by matching the plants such as gynura procumbens and perilla frutescens serving as component raw materials can really realize long-acting continuous prevention and alleviation of the DIBS symptoms; through mechanism research and analysis, the inventor finds that the product can obviously improve the unbalance condition of the brain-intestinal axis of a patient, reduce the level of 5-hydroxytryptamine in serum and colon, simultaneously relieve the over-activation of HPA axis, reduce the release of glucocorticoid corticosterone, realize the hit on a plurality of target targets, further integrally show the relieving effect of symptoms (such as the obvious reduction of the loose stool rate caused by diarrhea) and has no additional side effect.

Preferably, the raw materials in the plant composition can be replaced with corresponding plant extracts.

One skilled in the art can substitute at least one of the raw materials of the plant composition of the present invention with the corresponding plant extract (e.g., Gynura procumbens with Gynura procumbens extract) according to the actual production requirement, and the obtained product has the same technical effect.

Preferably, the plant composition comprises the following raw materials in parts by weight:

41-43 parts of gynura procumbens, 14-16 parts of purple perilla, 18-22 parts of lophatherum gracile, 22-24 parts of platycodon grandiflorum and 15-18 parts of poria cocos.

Under the preferable proportion, the obtained product has better DIBS symptom relieving effect.

The invention also aims to provide a preparation method of the plant composition for relieving diarrhea-predominant irritable bowel syndrome, which comprises the following steps:

(1) weighing the raw materials according to a ratio, mixing, drying and crushing to obtain mixed medicinal powder;

(2) adding the mixed medicinal material powder into a solvent, performing ultrasonic soaking, performing hot reflux extraction for 3-5 times, filtering, combining filtrate, performing reduced pressure concentration and spin drying treatment, and thus obtaining the plant composition capable of relieving diarrhea-predominant irritable bowel syndrome.

The preparation method of the plant composition capable of relieving diarrhea-predominant irritable bowel syndrome has simple operation steps and low equipment requirement, and can realize industrial mass production.

Preferably, the solvent comprises at least one of water, methanol, ethanol, propylene glycol, acetone;

more preferably, the solvent is water, and the mass ratio of the water to the mixed medicinal material powder is 20-30: 1.

The extraction of the raw materials of the product of the invention can be carried out with different solvents based on the actual requirements, and water is the best solvent based on the food-grade use safety characteristics of the product.

Preferably, the ultrasonic soaking time is 2-4 h, and the power is 400-800W.

The ultrasonic pretreatment is carried out on the mixed medicinal material powder under the time and the power, so that the yield of the extract can be improved.

Preferably, the time of each hot reflux is 1-1.5 h.

Preferably, the mesh number during filtration is 150-250 meshes.

The invention also aims to provide a pharmaceutical preparation for relieving diarrhea-predominant irritable bowel syndrome, which is prepared from the plant composition.

The plant composition is safe and non-toxic, has obvious effects of preventing, inhibiting and relieving diarrhea-predominant irritable bowel syndrome and stable property, can be effectively applied to preparing pharmaceutical preparations with corresponding efficacy requirements, and can be effectively applied to preventing and treating clinical symptoms, complications and related diseases caused by DIBS.

Preferably, the dosage form of the pharmaceutical preparation comprises any one of powder, tablet, granule, capsule and oral liquid.

The plant composition has stable property, and can play expected drug effect in different dosage forms of pharmaceutical preparations.

Preferably, the raw materials for preparing the pharmaceutical preparation also comprise processing aids;

more preferably, the processing aid comprises at least one of an excipient, a preservative, an antioxidant, and a lubricant.

The plant composition can be matched and combined with common carrier excipients for use, and plays a complete role according to the actual dosage form, and the addition of preservatives, antioxidants, lubricants and the like can further ensure the stability of the prepared product and prolong the shelf life of the product.

More preferably, the excipient comprises at least one of lactose, white sugar, mannitol, starch; the preservative comprises at least one of chlorobutanol, benzyl alcohol and dihydroxyacetic acid; the antioxidant comprises at least one of sulfite and ascorbic acid; the lubricant comprises at least one of magnesium stearate, calcium stearate and talcum powder.

The invention has the beneficial effects that: the invention provides a plant composition capable of relieving diarrhea-predominant irritable bowel syndrome, which takes gynura procumbens as a main component, and simultaneously takes perilla, lophatherum gracile, platycodon grandiflorum and poria cocos to generate synergistic effect together, so that the symptoms of the diarrhea-predominant irritable bowel syndrome can be remarkably improved and relieved, and the composition is safe and has no toxic or side effect. The invention also provides a preparation method of the plant composition and a pharmaceutical preparation prepared from the plant composition and capable of relieving diarrhea-predominant irritable bowel syndrome.

Detailed Description

The raw materials used in the examples of the present invention were purchased from commercial sources unless otherwise specified.

For better illustrating the objects, technical solutions and advantages of the present invention, the present invention will be further described with reference to specific examples, which are intended to be understood in detail, but not intended to limit the present invention.

Example 1

The embodiment of the plant composition for relieving diarrhea-predominant irritable bowel syndrome is disclosed in the invention.

The preparation method of the plant composition of this example comprises the following steps:

(1) weighing 42 parts of gynura procumbens, 15 parts of purple perilla, 20 parts of lophatherum gracile, 23 parts of platycodon grandiflorum and 16 parts of poria cocos according to a ratio, mixing, drying and crushing to obtain mixed medicinal powder;

(2) adding the mixed medicinal material powder into pure water (the mass ratio of water to the mixed medicinal material powder is 25:1), ultrasonically soaking for 3h, performing hot reflux extraction for 4 times, performing hot reflux for 1h each time, filtering by 200 meshes, combining filtrate, performing reduced pressure concentration and spin-drying treatment to obtain the plant composition capable of relieving diarrhea-predominant irritable bowel syndrome, wherein the calculated yield of the obtained product is 21.3% calculated by raw materials.

Example 2

The difference between the embodiment and the embodiment 1 is only that the addition ratio of the raw materials is as follows: 48 parts of gynura procumbens, 16 parts of purple perilla, 16 parts of lophatherum gracile, 25 parts of platycodon grandiflorum and 20 parts of poria cocos, and the calculated yield of the obtained product is 20.9% based on raw materials.

Example 3

The difference between the embodiment and the embodiment 1 is only that the addition ratio of the raw materials is as follows: 45 parts of gynura procumbens, 12 parts of purple perilla, 24 parts of lophatherum gracile, 22 parts of platycodon grandiflorum and 13 parts of poria cocos, and the calculated yield of the obtained product based on raw materials is 19.7%.

Comparative example 1

The comparative example differs from example 1 only in that the feedstock does not contain Gynura procumbens.

Comparative example 2

The comparative example is different from example 1 only in that the raw materials do not contain perilla and poria.

Comparative example 3

The comparative example differs from example 1 only in that the raw materials do not contain lophatherum gracile and platycodon grandiflorum.

Comparative example 4

The comparative example differs from example 1 only in that the raw materials do not contain platycodon grandiflorum and poria cocos.

Comparative example 5

The comparative example differs from example 1 only in that the raw materials do not contain perilla, lophatherum gracile, platycodon grandiflorum and poria cocos.

Examples of effects

In order to verify the irritable bowel syndrome relieving effect of the plant composition capable of relieving diarrhea-predominant irritable bowel syndrome, the products obtained in examples 1 to 3 and comparative examples 1 to 5 were subjected to a use test.

In order to achieve the above objects, the present invention refers to the experimental method of "southern university journal (medical edition) (2018,38(2): 81-84)", DIBS animal models prepared using senna leaves and constraint stress load to evaluate the biological activity of the composition: senna (Sennae folium) is the lobule of senna angustifolia or senna acutifolia of Leguminosae, and is used for purging heat, promoting diuresis, relieving heat accumulation, and treating constipation. In addition, the plant is rich in chrysophanol, rhein and other active components, is a stimulant laxative, and acts on colon through intestinal mucosa and nervous system to stimulate intestinal peristalsis; however, many studies to date have proved that the effect of DIBS modeling by gastric lavage with senna leaf aqueous extract alone is not significant, so that the present invention intervenes and establishes DIBS animal model by using restraint stress load as psychological factor on the basis of the administration of senna leaf aqueous extract to mice. The Restraint stress (stress) load test adopted by the invention is considered as a classical test mode for researching the interaction of the nerve-endocrine-immune system and the influence of the nervous system on the response of the organism function. The invention utilizes senna leaves and constraint stress load to prepare a mouse model, and effectively evaluates the improvement effect of the composition on DIBS.

Effect example 1

The specific test method of the effect example is as follows:

male 7-week-old kunming mice were used for the experiments, and the feeding conditions were as follows: the temperature is 23 +/-2 ℃, the humidity is 55 +/-5%, the illumination time is 12 h/day (7: 00-19: 00), water is freely drunk, and the experiment is carried out after feeding for one week. In addition, 50g of senna leaf is weighed, 30 times of water is added, the senna leaf is decocted for 30 minutes at 100 ℃, then the senna leaf is filtered by double-layer gauze to obtain supernatant, the extract is concentrated to 0.5g/mL, the extract is stored in a refrigerator at the temperature of 20 ℃ below zero, and the senna leaf needs to be preheated in a water bath at the temperature of 25 ℃ before use.

In the experiment, mice were randomly divided into a normal control group, a DIBS model group, a composition 1 group (example 1), a composition 2 group (example 2), a composition 3 group (example 3), and a control 1 group to a control 5 group (comparative examples 1 to 5), and each group had 8 mice. Mice in each administration group were fasted for 12 hours after gastric gavage (150mg/kg), and normal group and DIBS model group were given physiological saline in equal amounts. Subsequently, the mice of the DIBS model group and the administration group were subjected to gavage administration of an aqueous solution of senna leaves at a concentration of 0.5g/mL at a dose of 10mL/kg, and then the mice were placed under a 50mL restraint tube load for 2 hours, and after the restraint was released, the defecation was observed within 6 hours, and the mice were continuously molded for 5 days and observed.

The stool dilution rate is the total number of the stools and the stool dilution number of the mice 6h after the model is made by observing and calculating through a filter paper blotting method. The analysis of the stool dilution rate was carried out based on the presence or absence of stains on the filter paper and was calculated as follows, and the stool dilution rate (%) was the number of stool particles/total number of stool particles × 100%. Statistical methods the data obtained were analyzed using SPSS 20.0 statistical software, with P <0.05 indicating that the differences were statistically significant.

The test results are shown in table 1.

TABLE 1

As can be seen from table 1, compared with the mice in the DIBS model group, the average stool dilution rate of other test groups is reduced, but the reduction degree of part of the control groups is extremely low, and the effect is poor or negligible; the shit inhibition rate of mice in the composition group of the product obtained in the example 1 and used in the amount of 150mg/kg of the filling agent reaches 18.5 percent, which is far higher than the improvement effect (less than or equal to 10 percent) of other reference products (comparative products), which shows that the raw materials used in the plant composition provided by the invention mutually generate a synergistic effect, and the excellent DIBS symptom relieving effect is achieved under the integral action of indivisible parts. In addition, the curative effects of the compositions 1 to 3 are compared to discover that the composition 1 can more effectively improve the stool dilution rate of DIBS mice, and the proportion of the raw materials in the plant composition is also a key factor influencing the curative effect.

To continue to verify the above conclusions, dose-dependent test experiments were performed: the mouse model was cultured in the same manner as described above, and then the mice were randomly divided into a normal control group, a DIBS model group, a low dose, a medium dose and a high dose composition group (all using the product of example 1), 10 mice per group. Mice in each administration group were fasted for 12 hours after gavage (low dose composition group: 50 mg/kg; medium dose composition group: 150 mg/kg; high dose composition group: 450 mg/kg; and the normal group and DIBS model group were given an equal amount of physiological saline. Subsequently, the mice of the DIBS model group and the administration group were subjected to gavage administration of an aqueous solution of senna leaves at a concentration of 0.5g/mL at a dose of 10mL/kg, and then the mice were placed under a 50mL restraint tube load for 2 hours, and after the restraint was released, the defecation was observed within 6 hours, and the mice were continuously molded for 5 days and observed.

The test results are shown in tables 2 and 3.

TABLE 2

Experimental groups	One day	Three days	Five days
				Normal control group	0.00±0.00	0.00±0.00	0.00±0.00
DIBS model set	20.3±1.29*	23.6±1.02*	27.9±1.86*
				High dose composition group (450mg/kg)	14.7±2.48#	18.2±1.14#	22.7±2.49#
Medium dose composition group (150mg/kg)	17.1±1.81#	21.1±2.49#	25.3±2.17#
				Low dose composition group (50mg/kg)	18.6±2.47	22.3±3.48	26.8±2.79

P <0.05 compared to normal control group; compared with DIBS model group, # P <0.05

TABLE 3

From experiments, the inventor finds that the defecation time of normal mice is few, feces are dry and granular and have no mark or loose feces on filter paper, while the defecation time of mice in a DIBS model group is more, more stains exist on the filter paper, and obvious mucus exists around the feces, and from tables 2 and 3, after the plant composition disclosed by the invention is adopted, the first defecation time of the test mice is prolonged, the defecation number is reduced, the defecation amount is reduced, the effect is more obvious when the dosage is higher no matter the dosage is low, medium or high, and the plant composition disclosed by the invention has better dose dependence relationship.

Effect example 2

The "brain-intestine axis" refers to the connection between the gastrointestinal tract and the central system, through which information can be transmitted to the brain, and the central system can regulate the functions of the gastrointestinal tract such as digestion, absorption and excretion by releasing various hormones and neurotransmitters. Recent studies have found that irritable bowel syndrome patients suffer from different degrees of imbalance of the brain-intestinal axis, wherein 5-hydroxytryptamine (5-HT) presents higher level in intestinal mucosal tissues of DIBS patients and can be combined with 5-HT receptor III (5-HT3 receptor,5-HT3R) to cause gastrointestinal dysfunction. In fact, 5-HT3R antagonist can improve abdominal pain symptom and stool frequency of diarrhea patients, such as alosetron, but has been stopped to be used because it can cause adverse reactions such as ischemic colitis, and it can be seen that 5-HT and its receptor are important targets for treating DIBS. Therefore, the inventor also discusses whether the improvement effect of the plant composition for relieving diarrhea-predominant irritable bowel syndrome on DIBS model mice is related to 5-HT.

The test method is as follows:

(1) preparation of serum samples: the mice in the dose-dependent test experiment of effect example 1 were anesthetized by isoflurane and heart bled. Standing whole blood at room temperature for 1h, centrifuging at 5000rpm for 20min, and separating out serum;

(2) preparation of colon samples: colon tissue from experimental mice in effect example 1, according to 1: adding precooled PBS solution at a ratio of 10(m/v), homogenizing on ice, centrifuging at low temperature of 4 ℃ and 12000rpm for 15min, and collecting supernatant;

(3) detection of 5-HT: the level of 5-HT in mouse serum and colon tissue was determined using a mouse 5-HT enzyme linked immunoassay kit.

The results are shown in Table 4.

TABLE 4

Experimental groups	Serum (ng/mL)	Colon (ng/mL)
			Normal control group	373.2±54.8	1306.1±89.1
DIBS model set	716.8±98.4*	2147.9±112.6*
			High dose composition group (450mg/kg)	534.9±121.6#	1467.1±135.7#
Medium dose composition group (150mg/kg)	590.4±120.9#	1800.4±98.4#
			Low dose composition group (50mg/kg)	691.4±112.3	2013.7±147.9

P <0.05 compared to normal control group; compared to the DIBS model group, # P < 0.05.

As can be seen from Table 4, the 5-HT content in the serum and colon tissues of the mice of the DIBS model group is obviously increased compared with that of the mice of the normal control group, and the 5-HT content of the mice of the experimental group is reduced after the administration of the plant composition provided by the invention, wherein the 5-HT level inhibition effect in the serum and colon tissues of the mice of the medium-dose and high-dose groups is obvious, and the improvement effect of the plant composition for relieving diarrhea-predominant irritable bowel syndrome on the mice of the DIBS model is related to the 5-HT.

Therefore, the inventor detects the expression of the 5-HT3R protein in the colon tissue of the mouse and the application relation of the product by the western blot technology.

The specific experimental steps are as follows:

(1) homogenizing the colon tissue of the mouse taken out in the experiment, performing ice-bath lysis for 1h, centrifuging at the low temperature of 4 ℃ for 20min at the rotating speed of 12000rpm, collecting the supernatant, detecting the protein concentration by a BCA method, adding 1/4 volumes of 5 × loading buffer, and boiling at 100 ℃ for 5min for denaturation to obtain a protein sample.

(2) SDS-PAGE: protein loading 30 μ g, constant pressure 60V for 30min, and constant pressure 120V for 90 min.

(3) Film transfer: proteins were transferred from the gel onto a methanol activated PVDF membrane and transferred for 60min at a constant current of 300 mA.

(4) And (3) sealing: 5% skimmed milk was sealed with PVDF membrane at room temperature for 60 min.

(5) Antibody incubation: the 5-HT3R polyclonal antibody (Rabbit, 1:1000) was diluted in TBST and placed in a refrigerator at 4 ℃ overnight.

(6) And (3) HRP incubation: the goat anti-rabbit secondary antibody-HRP (1:3000) was incubated for 2h at room temperature at TBST dilution.

(7) ECL chemiluminescence: and (3) putting the strips into ECL working solution to be fully contacted, placing the strips in a solar energy luminescence workstation to be imaged, and carrying out semi-quantitative analysis on the protein strips by using ImageJ software.

The test results are shown in table 5.

TABLE 5

Experimental groups	Relative level of 5-HT3R
		Normal control group	1.01±0.22
DIBS model set	1.98±0.16*
		High dose composition group (450mg/kg)	1.25±0.13#
Medium dose composition group (150mg/kg)	1.35±0.21#
		Low dose composition group (50mg/kg)	1.82±0.16

As can be seen from Table 5, similar to 5-HT, the plant composition of the present invention significantly inhibited the level of 5-HT3R protein in mice in DIBS model group after use.

Effect example 3

IBS "brain-gut axis" imbalance is also manifested by an overactive "hypothalamic-pituitary-adrenal axis" (HPA axis), and indeed factors such as anxiety are also important causes for IBS induction, possibly related to activation of The HPA axis. Restraint stress is a good model of emotional anxiety, and can activate the HPA axis to promote the massive release of Glucocorticoids (GCs), the most common of which is Corticosterone (CORT) in mice and cortisol (Hydrocortisone) in humans. Therefore, the CORT level in the mice is also an important measure, and the CORT level in the dose-dependent test experiment in the effect example 1 is detected in the effect example.

The plasma CORT level was determined by the method reported in the literature (FASEB J.2020,34(8): 10998-11014).

The method comprises the following specific steps: after the experiment of effect example 1 is finished, the hearts of each group of mice are taken and placed in centrifugal tubes treated by anticoagulant, the centrifugation is carried out for 5min at the room temperature of 4000rpm, supernatant plasma is collected, 25 mu L of cortisol internal standard (4 mu g/mL) is added into 0.5mL of plasma sample, then 2mL of ethyl acetate is added for extraction, and an upper organic phase is collected. And adding 2mL of ethyl acetate for repeated extraction once, collecting the two extracts, washing the two extracts for 1 time by using 0.1mL of NaOH alkali solution, washing the extracts for 2 times by using distilled water, and then placing the extracts under nitrogen to blow and dry the ethyl acetate. Adding 100 μ L mobile phase (acetonitrile-water: 38-72) to dissolve to obtain analysis sample for subsequent HPLC analysis.

Drawing a standard curve: cortisone standard solutions were prepared at exact concentrations of 128, 64, 32, 16, 8 and 4ng/mL, respectively. To 50. mu.L of the standard solution, 50. mu.L of corrisol (0.075mg/mL) was added as an internal standard, i.e., a standard curve working solution containing the internal standard. The detection conditions are as follows: ultraviolet detection with a detection wavelength of 254 nm; a chromatographic column: 5C18 (4.6X 150mm,5 μm); mobile phase: acetonitrile-water (38-72); flow rate: 1mL/min, the sample amount is 20 mu L, linear regression analysis is carried out by taking the peak area of the standard substance/the peak area of the internal standard substance as the ordinate and the solubility (ng/mL) of the standard substance as the abscissa, a regression equation is obtained, and the CORT level in the plasma sample is calculated according to the regression equation.

The test results are shown in table 6.

TABLE 6

As can be seen from Table 6, the plasma CORT content of the DIBS model group mice is obviously increased compared with that of the normal group, while the plasma CORT content of the experimental group mice after being infused with the plant composition of the invention at different doses is obviously reduced, which shows that the plant composition of the invention can obviously inhibit the plasma CORT level.

Finally, it should be noted that the above embodiments are only used for illustrating the technical solutions of the present invention and not for limiting the protection scope of the present invention, and although the present invention is described in detail with reference to the preferred embodiments, it should be understood by those skilled in the art that modifications or equivalent substitutions can be made on the technical solutions of the present invention without departing from the spirit and scope of the technical solutions of the present invention.

Claims

1. The plant composition for relieving diarrhea-predominant irritable bowel syndrome is characterized by comprising the following raw materials in parts by weight:

2. The botanical composition for relieving diarrhea-predominant irritable bowel syndrome according to claim 1, wherein the botanical composition comprises the following raw materials in parts by weight:

3. The method of preparing the botanical composition for relieving diarrhea-predominant irritable bowel syndrome according to claim 1 or 2, comprising the steps of:

(2) adding the mixed medicinal material powder into water, ultrasonically soaking, performing hot reflux extraction for 3-5 times, filtering, combining filtrate, performing reduced pressure concentration and spin drying treatment, and thus obtaining the plant composition for relieving diarrhea-predominant irritable bowel syndrome.

4. The preparation method of the botanical composition for relieving diarrhea-predominant irritable bowel syndrome according to claim 3, wherein the mass ratio of the water to the mixed medicinal material powder is 20-30: 1.

5. The method for preparing the botanical composition for relieving diarrhea-predominant irritable bowel syndrome according to claim 3, wherein the ultrasonic immersion is performed for 2-4 hours at a power of 400-800W.

6. The method of preparing the botanical composition for relieving diarrhea-predominant irritable bowel syndrome according to claim 3, wherein the time period of the thermal reflux is 1-1.5 hours per time.

7. A pharmaceutical preparation for relieving diarrhea-predominant irritable bowel syndrome, which is prepared from the plant composition for relieving diarrhea-predominant irritable bowel syndrome according to claim 1 or 2.

8. The pharmaceutical preparation for relieving irritable bowel syndrome with diarrhea according to claim 7, wherein the pharmaceutical preparation is in a dosage form selected from the group consisting of powder, tablet, granule, capsule and oral liquid.

9. The pharmaceutical preparation for relieving irritable bowel syndrome with diarrhea according to claim 7, wherein the raw materials for preparing the pharmaceutical preparation further include a processing aid.

10. The pharmaceutical formulation for relieving irritable bowel syndrome with diarrhea according to claim 9, wherein the processing aid comprises at least one of a preservative, an antioxidant, and a lubricant.